Raphael Hall

Raphael Hall supports the Food and Drug Administration’s Office of Acquisition and Grant Services in executing mission-critical procurement activities that sustain the agency’s regulatory science infrastructure. He manages the acquisition of specialized laboratory equipment, analytical instrumentation, and technical services essential for drug safety evaluations, toxicological research, and medical device testing. His work ensures the FDA maintains high-precision capabilities to uphold public health standards through scientifically rigorous procurement practices aligned with federal acquisition regulations. Hall maintains consistent working relationships with niche scientific and technical service providers, including Tranquil Clinical and Research Consulting Services LLC, Toxicologic Pathology Associates Inc, and Progenics Pharmaceuticals Inc. These partnerships reflect a focus on contract research organizations and specialized laboratories that deliver expert analytical, preclinical, and regulatory support services. His procurement approach prioritizes technical expertise and domain-specific experience over volume, fostering long-term vendor collaborations grounded in compliance, data integrity, and scientific reliability. Hall’s procurement portfolio reflects a strong preference for open competition, with 100% of awards issued under no set-aside categories. This indicates a strategic emphasis on selecting the most technically qualified vendors regardless of socioeconomic status, consistent with the highly specialized nature of the FDA’s scientific requirements. While small business participation is not formally prioritized in his award patterns, his process remains fully compliant with all federal contracting statutes and emphasizes merit-based selection. His primary procurement focus centers on NAICS 811310 for commercial and industrial machinery repair and maintenance, reflecting his oversight of calibration, servicing, and lifecycle support for high-value lab equipment, and NAICS 334519 for other measuring and controlling device manufacturing, indicating direct acquisition of precision analytical instruments. His expertise lies at the intersection of regulatory science and technical procurement, ensuring that the FDA’s laboratory infrastructure remains operational, compliant, and scientifically robust.